Search Results

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Communications Officer Will Roberts will provide a corporate presentation on September 12, 2023, at 9:30 AM EDT during the H.C. Wainwright 25th Annual Global Investment Conference.

HiberCell, a clinical-stage biotechnology company dedicated to addressing mechanisms of treatment resistance, cancer relapse, and metastasis, today announced the successful completion of its Phase 1 study of the novel PERK inhibitor, HC-5404, in solid tumors along with two pre-clinical publications in one of the leading journals of AACR, Clinical Cancer Research (CCR).

HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address advanced cancer and cancer resistance, is pleased to announce the first patient dosed in a clinical trial evaluating HC-7366 in combination with standard of care agents venetoclax and azacitidine for advanced acute myeloid leukemia (AML).

Clene Inc. today announced that management will present at H.C. Wainwright’s 5th Annual Neuro Perspective Virtual Conference and host 1x1 investor meetings.

BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”) today announced that Jonathan Solomon, Chief Executive Officer of BiomX, will present at the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage on November 30, 2022.

Lantern Pharma will present virtually on Thursday, March 7th at 2 pm Eastern.

Aptinyx to Participate in H.C. Wainwright 1st Annual Mental Health Conference.